The drug is approved as Lyxumia in more than 60 countries
WatchPAT approved for diagnostic testing on patients as young as 12 years old
Antibody adds to toolkits of biologics manufacturers, regulators
EHRs do not increase inpatient mortality, adverse safety events
Respondents worry about gene editing and synthetic blood
Risks outweigh benefits in certain patients
Experts find little evidence to support routine screening in adults

P&T July 2016
Table of Contents


A new test model starting in five regions in 2017 seeks better integration of pharmacists into the Medicare Part D Medication Therapy Management program, which has severely underperformed since the Part D benefit took effect in 2006.
Childhood vaccination is one of the most effective public health strategies to control and prevent disease, but some parents decline or delay vaccinating their children. A variety of measures have been suggested to overcome vaccine noncompliance.
National treatment guidelines for bacterial meningitis were published in 2004, but no assessment of their use has been reported. In retrospective chart reviews at two hospitals, recommended antibiotic regimens were given to 52.6% of the 38 patients.
In a retrospective review, the prevalence of delirium did not differ among intensive care unit patients who received either dexmedetomidine or propofol alone for 24 hours or more. Propofol was linked with more coma and shorter hospital stays.
Meeting Highlights
We report on key Digestive Disease Week sessions that focused on hepatitis C virus and Clostridium difficile infection, colonoscopy preparation, irritable bowel syndrome, and Crohn’s disease. We also review major American Society of Clinical Oncology sessions on breast, pancreatic, ovarian, skin, and brain cancers and multiple myeloma.


Medication Errors
We all have a role in preventing fentanyl patch tragedies
Prescription: Washington
HHS walks a middle ground in final nondiscrimination rule
Approvals, new indications, regulatory activities, and more
Defibrotide sodium (Defitelio) for hepatic veno-occlusive disease; emtricitabine/tenofovir alafenamide (Descovy) for human immunodeficiency virus infection; and infliximabdyyb (Inflectra) for Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis
Drug Forecast
Brexpiprazole (Rexulti): a new monotherapy for schizophrenia and adjunctive therapy for major depressive disorder